SFC
ALNY icon

SYM Financial Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

SYM Financial Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-729
Closed -$290K – 417
2025
Q4 		$290K Buy
729
+54
+8% +$23.9K 0.03% 232
2025
Q3 		$308K Sell
675
-269
-28% -$110K 0.03% 214
2025
Q2 		$308K Sell
944
-70
-7% -$19.4K 0.03% 203
2025
Q1 		$274K Buy
1,014
+51
+5% +$13.1K 0.03% 186
2024
Q4 		$227K Buy
963
+16
+2% +$4.21K 0.03% 210
2024
Q3 		$260K Buy
947
+55
+6% +$14.3K 0.03% 135
2024
Q2 		$217K Buy
+892
New +$141K 0.03% 141

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SYM Financial Corp's ALNY Position: Q1 2026 in Review

SYM Financial Corp sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 729 shares — an estimated $290K sold.

SYM Financial Corp first reported a position in ALNY in Q2 2024 and held it in 7 quarters. The position peaked at $308K in Q2 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • SYM Financial Corp reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SYM Financial Corp sold 729 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $290K.
  • SYM Financial Corp first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • SYM Financial Corp's Alnylam Pharmaceuticals position peaked at $308K in Q2 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SYM Financial Corp's 13F filing for Q1 2026, filed 8 May 2026.